AbCellera Biologics (ABCL) Shares Outstanding (Weighted Average) (2020 - 2025)
AbCellera Biologics' Shares Outstanding (Weighted Average) history spans 6 years, with the latest figure at $298.9 million for Q3 2025.
- For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 1.68% year-over-year to $298.9 million, compared with a TTM value of $298.9 million through Sep 2025, up 1.68%, and an annual FY2019 reading of $151.3 million, changed N/A over the prior year.
- Shares Outstanding (Weighted Average) for Q3 2025 was $298.9 million at AbCellera Biologics, roughly flat from $298.5 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $298.9 million in Q3 2025, with the low at $269.7 million in Q1 2021.
- Average Shares Outstanding (Weighted Average) over 5 years is $287.7 million, with a median of $288.9 million recorded in 2023.
- Year-over-year, Shares Outstanding (Weighted Average) soared 83.01% in 2021 and then grew 1.36% in 2023.
- Tracing ABCL's Shares Outstanding (Weighted Average) over 5 years: stood at $278.9 million in 2021, then increased by 2.29% to $285.3 million in 2022, then rose by 1.46% to $289.5 million in 2023, then rose by 1.53% to $293.9 million in 2024, then grew by 1.68% to $298.9 million in 2025.
- Per Business Quant, the three most recent readings for ABCL's Shares Outstanding (Weighted Average) are $298.9 million (Q3 2025), $298.5 million (Q2 2025), and $297.7 million (Q1 2025).